Fennec says Phase 2 Japan study shows Pedmark cuts cisplatin-linked hearing loss to 24% in pediatric, AYA patients
FENC•FENC•FENC•FENC•Fennec Pharmaceuticals announced detailed Phase 2 STS-J01 results for Pedmark in Japan, presented at the SIOP 2026 annual meeting.
The trial showed reduced cisplatin-related hearing loss in pediatric and adolescent or young adult (AYA) patients with localized, non-metastatic solid tumors.
The data supported no apparent reduction in tumor response with delayed Pedmark dosing, addressing a key adoption concern for clinicians.
The safety profile aligned with prior experience for Pedmark; no serious adverse event was attributed to the drug.
Fennec is pursuing Japanese registration, signaling a potential new market expansion path for Pedmark.
